RedHill Biopharma (RDHL) Equity Average (2023 - 2024)

Generated on {Timestamp} © BusinessQuant.com

Generated on {Timestamp} Powered by

RedHill Biopharma (RDHL) has disclosed Equity Average for 2 consecutive years, with -$1.3 million as the latest value for Q4 2024.

• Quarterly Equity Average rose 94.36% to -$1.3 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$1.3 million through Dec 2024, up 94.36% year-over-year, with the annual reading at -$1.3 million for FY2024, 94.36% up from the prior year.
• Equity Average for Q4 2024 was -$1.3 million at RedHill Biopharma, up from -$23.2 million in the prior quarter.
• The five-year high for Equity Average was -$1.3 million in Q4 2024, with the low at -$23.2 million in Q4 2023.

Peer Comparison